"Targeting KRAS has been a 40-year quest leaving patients with limited treatment options. In just under two years in the clinic, we have seen encouraging early efficacy and safety data across a number of solid tumors," said
Sotorasib Activity in Patients With Advanced Colorectal Cancer
CRC is the second leading cause of cancer deaths worldwide.1 It is the third most commonly diagnosed cancer globally and incidence is expected to grow by more than 20% over the next decade.2 For patients with previously treated metastatic CRC receiving standard therapies, unmet need remains high, with median progression-free survival (PFS) of about 2 months and response rates of less than 2%.3,4
This Phase 1 dose escalation study evaluated 42 heavily pretreated patients with advanced KRAS G12C-mutant CRC (data cut-off of
In the 960 mg once-daily target dose cohort, the objective response rate (ORR) was 12% (3/25) and the disease control rate (DCR) was 80% (20/25). Median PFS was 4.2 months and overall survival (OS) had not been reached after a median follow-up of almost 8 months. Tumor shrinkage was observed in 11 of 23 patients with available post-baseline tumor data.
Across all dose levels, the majority of patients achieved disease control, with an ORR of 7.1% and a DCR of 76.2%. Disease stability was maintained for a median of 4.2 months. Median PFS was 4.0 months and median OS was 10.1 months. Tumor shrinkage was observed in 18 of 39 patients with available post-baseline tumor data across all doses.
"There is currently a tremendous treatment gap for patients with advanced KRAS G12C-mutant colorectal cancer," said
Disease progression was the most common reason for treatment discontinuation. The majority of treatment-related adverse events (TRAEs) were Grade 1 and 2. Only two TRAEs were Grade 3 (diarrhea and anemia). There were no Grade 4 or higher TRAEs.
Sotorasib Activity in Patients With Advanced Solid Tumors Other Than NSCLC or CRC
Data were evaluated for 25 heavily pretreated patients with advanced KRAS G12C-mutant solid tumors other than CRC or NSCLC. These patients had received a median three prior lines of therapy with a median follow-up of 4.3 months.
These data demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors, including pancreatic, appendiceal and endometrial cancer. Partial responses were confirmed in three patients with appendiceal, melanoma and endometrial cancer, respectively. Six of eight evaluable patients with pancreatic cancer achieved stable disease, and three had approximately a 30% reduction in tumor burden from baseline. Tumor shrinkage was observed in 13 of 19 evaluable patients with available post-baseline tumor data across all tumor types.
A complete listing of
The subject of almost four decades of research, the RAS gene family contains the most frequently mutated oncogenes in human cancers.5,6 Within this family, KRAS is the most prevalent variant and is particularly common in solid tumors.5 A specific mutation known as KRAS G12C is found in approximately 13% of non-small cell lung cancers, 3% to 5% of colorectal cancers and 1% to 2% of numerous other solid tumors.7-9 The KRASG12C protein has been considered "undruggable" due to a lack of traditional small molecule binding pockets on the protein. Amgen is exploring the potential of KRASG12C inhibition across a broad variety of solid tumor types.
The CodeBreaK clinical trial program for
CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutant solid tumors. Eligible patients were heavily pretreated with at least two or more prior lines of treatment, consistent with their tumor type and stage of disease. The primary endpoint for the Phase 1 study is safety, and key secondary endpoints include objective response rate (assessed every six weeks), duration of response and progression-free survival. Patients were enrolled in four dose cohorts: 180 mg, 360 mg, 720 mg and 960 mg, taken orally once a day.
For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.
To learn more about
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
This news release contains forward-looking statements that are based on the current expectations and beliefs of
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the
CONTACT: Amgen, Thousand Oaks
1 Bray F, et al. CA Cancer J Clin. 2018;68:394-424.
2 Arnold, M, et al. Gut. 2017;66:683–691.
3 Mayer RJ, et al. N Engl J Med. 2015;372:1909-1919.
4 Grothey A, et al.
5 Cox AD, et al. Nat Rev Drug Discov. 2014;13:828-851.
6 Fernandez-Medarde A, et al. Genes Cancer. 2011;2:344-358.
7 Biernacka A, et al. Cancer Genet. 2016;209:195-198.
8 Neumann J, et al. Pathol Res Pract. 2009;205:858-862.
9 Zhou L, et al. Med Oncol. 2016;33:32.
View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-presents-new-amg-510-clinical-data-across-multiple-solid-tumors-during-asco20-virtual-scientific-program-301067486.html